Observational studyBMC cardiovascular disorders2025
Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients.BMC cardiovascular disorders · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
introductionHeart failure (HF) is a major cause of hospitalization and mortality. Early initiation of guideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction (HFrEF). This study assesses the impact of starting GDMT with an SGLT2i in newly diagnosed HFrEF patients. MATERIALS AND
methodsThe XXXX1 multicenter prospective registry enrolled consecutive newly diagnosed HFrEF patients between October 2021 and March 2022 to evaluate the influence of medical treatment schedules in newly diagnosed HFrEF. In this substudy, patients were grouped by initial GDMT with or without an SGLT2i. Over six months, clinical variables, echocardiographic and laboratory parameters, and clinical events (hospitalizations, emergency visits) were collected. The primary aim was to compare GDMT implementation (quadruple therapy rates), with secondary aims assessing efficacy (target doses) and safety (adverse events).
resultsOf 518 patients, 400 initiated treatment with an SGLT2i, while 118 did not, with no differences in the baseline characteristics. At six months, 81.5% of patients who started with an SGLT2i were on quadruple therapy, compared to 61.2% in the non-SGLT2i group (p = 0.0001). The group starting with an SGLT2i showed a significant increase in left ventricular ejection fraction at 3 months (14.2% vs 10.6%; p = 0.023) and preservation of renal function (GFR change: -4.7 vs + 0.4 mL/min; p = 0.011). Furthermore, patients who started on SGLT2i showed a trend toward fewer HF decompensations and a significantly lower rate of non-cardiovascular hospitalizations.
conclusionsInitiating GDMT with an SGLT2i facilitates the early implementation of quadruple therapy, improves LVEF, preserves renal function, and shows a trend toward reducing HF decompensations. SGLT2i initiation also demonstrated a favourable safety profile, supporting their early use in newly diagnosed HFrEF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.